Publication: 3698

Polygenic risk scores for blood pressure to assess the risk of severe bevacizumab-induced hypertension in cancer patients (Alliance)
      QxMD      Google Scholar   
Citation:
Clin Pharmacol Ther vol 112 (2) 364-371
Year:
2022
Type:
Manuscript
Funding:
NCTN
Endpoint:
Secondary-not-in-original
Analysis:
Meta-Analysis
Data Sharing:
Alliance-data-source,-external-user
Status:
Presented/Published
Citation Status:
pmc-release
Note:
Methodological:
No
Biospecimen:
No
SDC:
No
Book Volume:
11
Parents:
None
Children:
None
Program:
TRP
Primary Committee:
Correl Sci NOS
Sec. Committees:
   
Pharmas:
 
Grants:
U10CA180821, U10CA180882, U24CA196171, UG1CA232760, UG1CA233373, AHA Award Number 826128  
Corr. Author:
 
Authors:
               
Networks:
LAPS-NC007   
Study
Alliance-A152114
Multiple Studies, or Legacy Studies in Alliance Study:
CALGB-40502, CALGB-40503, CALGB-80303, CALGB-90401
Phases:
N/A, 3
Keywords:
bevacizumab, hypertension, polygenic risk score, blood pressure